Medicine:Septic shock

From HandWiki
Short description: Dangerously low blood pressure due to damage from an organ infection

Septic shock
Sepsis is one of the most common causes of death in critically ill patients in intensive care units. Oil by Gabriël Metsu.
SpecialtyInfectious disease, critical care medicine, emergency medicine
Purpura caused by thrombocytopenia on right hand in patient with septic shock

Septic shock is a potentially fatal medical condition that occurs when sepsis, which is defined as an abnormal immune response to infection that leads to life threatening organ dysfunction, leads to dangerously low blood pressure and abnormalities in cellular and metabolic dysfunction.[1] The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) defines septic shock as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone.[2] Patients with septic shock are cared for in the emergency department and intensive care units.[1]

Causes

Septic shock is a result of a systemic response to infection or multiple infectious causes.[3] Sepsis always precedes septic shock; therefore, the causes of sepsis are also the causes of septic shock.

More than 80 percent of sepsis cases are caused by respiratory, genitourinary, skin and soft tissue, and gastrointestinal infections.[4] Interestingly, pneumonia is the most common cause of sepsis.[5] Indwelling devices, such as pacemakers or knee replacements can also lead to sepsis. Severe infections, such as meningitis, encephalitis, and endocarditis are also causes of sepsis. All together indwelling devices and severe infections make up 1 percent of sepsis cases.[6] Bacteria are the microorganisms responsible for a majority of cases of sepsis.[6] About 62 percent are caused by gram negative bacteria and 47 percent are caused by gram positive bacteria.[6] A small number of patients can have sepsis brought on by fungi, parasites, or viral infections.[1] It is also possible that sepsis can be caused by multiple simultaneously occurring infections.[7]

Pathophysiology

The pathophysiology of septic shock is not entirely understood, but it is known that a key role in the development of severe sepsis is played by an immune and coagulation response to an infection. Both pro-inflammatory and anti-inflammatory responses play a role in septic shock.[8] Septic shock involves a widespread inflammatory response that produces a hypermetabolic effect. This is manifested by increased cellular respiration, protein catabolism, and metabolic acidosis with a compensatory respiratory response.[9]

Both gram positive and gram negative bacteria are the most common causes of septic shock.[10] Toxins produced by pathogens cause an immune response; in gram-negative bacteria these are endotoxins, which are bacterial membrane lipopolysaccharides (LPS).[10][11]

Cytokines released in a large-scale inflammatory response result in massive vasodilation, increased capillary permeability, decreased systemic vascular resistance, and low blood pressure.[3][12] Finally, in an attempt to offset decreased blood pressure, myocardial dysfunction occurs with both systolic (decreased ability of the heart to squeeze) and diastolic (decreased ability of the heart to stretch to accommodate appropriate blood volume) dysfunction.[13]

Gram-positive

In gram-positive bacteria, these are exotoxins or enterotoxins, which may vary depending on the species of bacteria.[14] These are divided into three types.[14] Type I, cell surface-active toxins, disrupt cells without entering, and include superantigens and heat-stable enterotoxins.[14] Type II, membrane-damaging toxins, destroy cell membranes to enter and include hemolysins and phospholipases.[14] Type III, intracellular toxins or A/B toxins interfere with internal cell function and include toxins secreted by streptococcus pyogenes or staphylococcus aureus.[14][15]

Gram-negative

In gram-negative sepsis, a free LPS attaches to a circulating LPS-binding protein, and the complex then binds to the CD14 receptor on monocytes, macrophages, and neutrophils.[16] Engagement of CD14 (even at doses as minute as 10 pg/mL) results in intracellular signaling via an associated "Toll-like receptor" protein 4 (TLR-4).[16] This signaling activates nuclear factor kappaB (NF-κB), which leads to transcription of several genes that trigger a proinflammatory response.[17] This results in significant activation of mononuclear cells and synthesis of effector cytokines such as IL-1, IL-6, and TNF-α.[18] TLR-mediated activation helps to trigger the innate immune system to efficiently eradicate invading microbes, but the cytokines they produce also act on endothelial cells.[16] There, they have a variety of effects, including reduced synthesis of anticoagulation factors such as tissue factor pathway inhibitor and thrombomodulin.[19] The effects of the cytokines may be amplified by TLR-4 engagement on endothelial cells.[16][19]

In response to inflammation, a compensatory reaction of production of anti-inflammatory substances such as IL-4, IL-10 antagonists, IL-1 receptor, and cortisol occurs.[20] This is called compensatory anti-inflammatory response syndrome (CARS).[21] Both the inflammatory and anti-inflammatory reactions are responsible for the course of sepsis and are described as MARS (Mixed Antagonist Response Syndrome).[20] The aim of these processes is to keep inflammation at an appropriate level. CARS often leads to suppression of the immune system, which leaves patients vulnerable to secondary infection.[8] It was once thought that SIRS or CARS could predominate in a septic individual, and it was proposed that CARS follows SIRS in a two-wave process. It is now believed that the systemic inflammatory response and the compensatory anti-inflammatory response occur simultaneously.[21]

At high levels of LPS, the syndrome of septic shock supervenes; the same cytokine and secondary mediators, now at high levels, result in systemic vasodilation (hypotension), diminished myocardial contractility, widespread endothelial injury, activation causing systemic leukocyte adhesion and diffuse alveolar capillary damage in the lung, and activation of the coagulation system culminating in disseminated intravascular coagulation (DIC).[20]

The hypoperfusion from the combined effects of widespread vasodilation, myocardial pump failure, and DIC causes multiorgan system failure that affects the liver, kidneys, and central nervous system, among other organ systems. Recently, severe damage to liver ultrastructure has been noticed from treatment with cell-free toxins of Salmonella.[22]

The ability of TLR4 to respond to a distinct LPS species is clinically important. Pathogenic bacteria may employ LPS with low biological activity to evade proper recognition by the TLR4/MD-2 system, dampening the host immune response and increasing the risk of bacterial dissemination.[20] On the other hand, such LPS would not be able to induce septic shock in susceptible patients, rendering septic complications more manageable.[20] Yet, defining and understanding how even the smallest structural differences between the very similar LPS species may affect the activation of the immune response may provide the mechanism for the fine tuning of the latter and new insights to immunomodulatory processes.[23]

Diagnosis

Definitions

Sepsis is the precipitating condition to septic shock, hence the diagnostic criteria for sepsis are pertinent to the diagnosis of septic shock.[24]

There are three different systems to diagnosis sepsis.[1] These are the systemic inflammatory response syndrome (SIRS) criteria, the full Sequential Organ Failure Assessment (SOFA), and the quick version of SOFA (qSOFA).[25] The most recent gathering of professionals to discuss the topic of sepsis was called "sepsis-3" and set forth the latest guidelines for the diagnosis and management of sepsis.[26]

SIRS

The SIRS criteria were recently excluded from sepsis-3, but are still the most used diagnostic tool for identifying sepsis.[27] A patient that meets SIRS criteria has a possible, or documented, source of infection plus at least two or more of the criteria listed below.[11]

  • Tachypnea (fast rate of breathing), which is defined as more than 20 breaths per minute, or when testing blood gas, a PaCO2 less than 32 mm Hg, which signifies hyperventilation
  • White blood cell count either significantly low (< 4000 cells/mm3), or elevated (> 12000 cells/mm3)
  • Tachycardia (rapid heart rate), which in sepsis is defined as a rate greater than 90 beats per minute
  • Altered body temperature: Fever > 38.0 °C (100.4 °F) or hypothermia < 36.0 °C (96.8 °F)

Documented evidence of infection may include positive blood culture, signs of pneumonia on chest x-ray, or other radiologic or laboratory evidence of infection.[3] Signs of end-organ dysfunction are present in septic shock, including kidney failure, liver dysfunction, changes in mental status, or elevated serum lactate.[12] One limitation of the SIRS criteria is that it can be present in many non-infectious conditions, such as autoimmune conditions, pancreatitis, recent surgery, or vasculitis.[28]

qSOFA and SOFA

qSOFA is another set of criteria used to diagnose sepsis and help clinicians identify sepsis in settings other than the ICU.[1] It's counterpart SOFA is used exclusively in the ICU.[28]

In the SOFA criteria, there are three criteria, which are listed below.[28]

  • respiratory rate of 22 breathes per minute or greater
  • altered mental status
  • systolic blood pressure of 100 mg or less

Patients meet SOFA criteria, and therefore have sepsis, when they fulfill 2 or more of the above criteria.[12] qSOFA is typically limited as it is known mainly identify patients who present late in the course of sepsis.[29]

SOFA criteria is used in critically ill patients and assesses the severity of dysfunction in the 6 organ systems.[30] At the time of ICU admission the score is calculated as the baseline. After this the score is calculated every 48 hours.[31] Baseline is a score of zero which indicates no sepsis.[11] An increase in score by 2 or more points indicates sepsis and an increased mortality of 20%.[1]

Septic shock

Septic shock is a subclass of distributive shock, a condition in which abnormal distribution of blood flow in the smallest blood vessels results in inadequate blood supply to the body tissues, resulting in ischemia and organ dysfunction.[32] Septic shock refers specifically to distributive shock due to sepsis as a result of infection.[32]

Originally, septic shock was identified in patients based only on the presence of hypotension.[33] However, in recent years, it has been found that hypotension is a later manifestation of septic shock.[34] Specifically, lack of blood flow to the tissue (tissue hypoperfusion) has been found to occur well before hypotension in cases of septic shock.[35] Therefore, a lactate measurement has become an integral part to the diagnosis of septic shock.[34] This is because lactate is a marker of tissue hypoperfusion as this metabolic product is only produced by metabolic processes that occur in the absence of adequete oxygen supply to the tissue.[36] A lactate level of 18 mg/dL (or 2 mmol per L) is diagnostic for septic shock according to sepsis-3.[28] Another diagnostic criterion for septic shock is vasopressor therapy required to maintain a mean arterial pressure of 65 mmHg.[37]

Signs and symptoms

General

The signs and symptoms of sepsis and septic shock vary depending on the precipitating cause.[12] However, general signs and symptoms include fevers, rigors, hypothermia, diaphoresis, malaise.[12] Although fever is the most common manifestation of sepsis it can be absent in some cases.[38] In particular, fever can be absent in immunocompromised patients, older patients, and patients with chronic alcohol abuse.[1] Additionally, it is important to note that higher mortality has been associated with patients presenting with hypothermia.[38]

Cardiac

New murmur, tachycardia, hypotension, and warm and flushed skin.[10]

Gastrointestinal

Abdominal rigidity, abdominal pain, vomitting, diarrhea, dysphagia, and abnormal distension.[10]

Petechial rash in a patient with septic shock.
Picture of splinter hemorrhage in septic shock related to endocarditis.

Pulmonary

Cough, pleuritic chest pain, tachypnea, shortness of breath, and sore throat.[2]

Neurologic

Altered mental status, headache, saddle anesthesia, neck stiffness or rigidity, and seizures.[39]

Musculoskeletal

Joint pains, mylagias, edema, weakness, and crepitus.[40]

Genitourinary

Dysuria, hematuria, frequency, costovertebral angle tenderness, pyuria, vaginal bleeding, and vaginal discharge.[41]

Dermatologic

Petechiae, bullous lesions, erythema, rash, splinter hemorrhages, bruising, and purulent lesions.[42]

Diagnostic tools

Imaging

Chest X-rays are typically indicated for every case of sepsis as pneumonia is the most common cause of sepsis.[43] Depending on the clinical situation other imaging studies can be ordered. If endocarditis is suspected echocardiography is indicated.[44] CT scans of the chest can also be used when empyema or infectious effusions are suspected.[45] CT scans of other areas of the body can be used if abscesses are suspected.[46]

Laboratory testing

A large amount of laboratory tests are indicated when sepsis is suspected. In terms of cultures, typically clinicians order two sets of peripheral blood cultures, urine cultures, stool cultures, sputum, and skin cultures.[33] Special cultures, such as cerebrospinal, joint, or pleural cultures, are only ordered in certain clinical scenarios and are not the standard of care.[33] Other laboratory tests ordered in the setting of sepsis include complete blood count with differential, basic metabolic panel, urinalysis, coagulation studies, and liver enzyme studies.[29] Lastly, acid and base abnormalities are common in the setting of sepsis, therefore, arterial and venous blood samples are ordered.[47]

Sepsis biomarkers

The two main biomarkers used for sepsis and septic shock are lactate and procalcitonin.[1]

Lactate is used because lactate is produced in the body as a result of tissues receiving inadequate oxygen supply due to poor blood flow.[36] Since tissues do not receive adequate blood flow in septic shock, lactate can be used to detect if a patient is in a state of septic shock.[36] As mentioned above, a lactate level of 18 mg/dL (2 mmol per L) is diagnostic criteria for septic shock according to sepsis-3.[28] Lactate levels are obtained when sepsis is first suspected.[2] If the levels are elevated at that time then the measurement of lactate is repeated every four to six hours until the levels become normal again.[33]

Procalcitonin can be used as an indicator for sepsis because it is a marker for inflammation produced by cytokines and bacterial endotoxins.[48] A procalcitonin level of 0.05 ng/mL is considered normal and patients with procalcitonin levels less than 0.25 ng/mL have low likelihood of sepsis.[49] Several studies have shown that the severity of sepsis and the procalcitonin levels have a statistically significant relationship.[49] Although no specific diagnostic cutoffs for procalcitonin levels currently exist, some trials have noted that patients with mean levels of 9.6 ng/mL typically have sepsis with no shock, and patients with mean levels of 32.7 ng/mL typically have septic shock.[50]

Treatment

Treatment primarily consists of the following:

  1. Giving intravenous fluids[51]
  2. Early antibiotic administration[51]
  3. Early goal directed therapy[51]
  4. Rapid source identification and control
  5. Support of major organ dysfunction

Fluids

Because lowered blood pressure in septic shock contributes to poor perfusion, obtaining vascular access and performing fluid resuscitation is an initial treatment to increase blood volume. Patients demonstrating sepsis-induced hypoperfusion should be initially resuscitated with at least 30 ml/kg of intravenous crystalloid within the first three hours.[1] It is considered acceptable to infuse one liter boluses within the first 30 minutes.[3]

Fluid resuscitation helps in the treatment of septic shock because it enhances preload and cardiac output, which improves oxygen delivery.[12]

Crystalloids such as normal saline and lactated Ringer's solution are recommended as the initial fluid of choice, while the use of colloid solutions such as hydroxyethyl starch have not shown any advantage or decrease in mortality.[33] When large quantities of fluids are given, administering albumin has shown some benefit.[29]

After initial fluid resuscitation, frequent reassessment of patient fluid balance is required to avoid over- or under- hydration.[29] This is of more importance in patients with heart failure, acute lung injury, or chronic renal disease as volume overload can be devastating to these patients.[52] Fluid balance can be assessed in many ways such as, dynamic blood pressure response, urine output (should be greater than 0.5 mL per hour), lactate clearance, ultrasound of the inferior vena cava, passive leg raise, and pulse pressure variation.[1]

Fluid administration should be restricted in the later components of sepsis management.[53] At 72 hours patients should ideally have a fluid balance of zero.[53] This is because it has been shown that each one liter of over-hydration increases the risk of death.[53]

Antibiotics

General approach

Early initiation of antibiotic therapy is associated with better outcomes in multiple studies.[3] At one point it was recommended that antibiotics be administered one hour after initial recognition of sepsis.[1] However, several subsequent studies have found that there was no difference in mortality between patients receiving antibiotics within one hour and those receiving them beyond one hour.[1] However, it has been shown that mortality rates are higher for those who received antibiotic therapy after three hours.[1]

At first antibiotic therapy should be broad and based on a combination of factors, such as the suspected infection site, clincal context (community or hospital acquired), most likely pathogen, and local resistance patterns.[37] Once cultures definitively reveal the pathogen responsible for the infection, the antibiotic selection can be narrowed or changed as appropriate.[29] This specific approach reduces treatment cost, avoids drug toxicity, and reduces the risk of antimicrobial resistance.[54]

De-escalation of antibiotic therapy is controversial and no consensus has been reached in the literature.[29] Factors that are used to decide de-escalation of antibiotic therapy include the use of biomarkers, such as a decreasing procalcitonin, to monitor response to therapy or clinical progress during treatment.[55]

Typically most patients can be effectively treated with 7-10 days of antibiotic therapy.[29] However, specific infections such as endocarditis and osteomyelitis and infections caused by indwelling devices that cannot be removed may require longer durations of antibiotic therapy.[1]

Specific antibiotic treatment choices for different infections causing sepsis

Meningitis

To treat meningitis-related sepsis, one can administer vancomycin, ceftriaxone, ampicillin, and dexamethasone (a corticosteroid used as an anti-inflammatory to reduce neuro complications).[56] If the patient has an allergy to beta-lactams, one can administer vancomycin, moxifloxacin, and trimethoprim/sulfamethoxazole (TMP-SMX).[56] If herpes encephalitis is suspected then acyclovir can be administered.[56]

Pulmonary infection

For community-acquired pneumonia without risk for drug resistance, a fluoroquinolone can be given, or ceftriaxone and azithromycin, or ceftriaxone and doxycycline.[57] For community-acquired pneumonia with risk for drug resistance or hospital-acquired pneumonia, a fluoroquinolone can be given, or zoysn, or cefepime, or carbapenem.[58] If the patient has a beta lactam allergy one can give aztreonam and a fluoroquinolone.[57] Vancomycin should be added in the cases of empyema.[58]

Skin and soft-tissue infection

Can administer vancomycin or linezolid with zosyn, or carbapenem, or cefepime and metronidazole.[59] If a necrotizing infection is suspected then a carbapenem with vancomycin and clindamycin is recommended and surgery should also be consulted.[60]

Intrabdominal infections

Can administer zoysn, or carbapenem, or primaxin, or flagyl. If the patient has a beta lactam allergy then vancomycin with aztreonam and metronidazole can be given.[61] Surgery should also be consulted in cases of intrabdominal infection.[61]

Neutropenia with infection

Can administer cefepime, or zoysn, or carbapenem, or ceftazidime. If the patient has a beta lactam allergy then aztreonam with vancomycin or ciprofloxacin with clindamycin can be given.[62] If the patient is neutropenic with septic shock, pneumonia, has an infected venous catheter, skin and soft-tissue infection, gram-positive bacteremia, or mucositis then vancomycin should be added.[62]

Unknown infections

Can administer vancomycin with levofloxacin.[29]

Vasopressors

The first line vasopressor for septic shock is norepinephrine.[29] This is indicated when patients do not have their mean arterial pressure restored to 65 mmHg or greater after initial fluid resuscitation.[29] It has been shown that vasopressor therapy increases survival in patients with septic shock.[63] It has also been shown that the mortality of patients with septic shock increases by 5% per hour that the vasopressor is not given.[63] Norepinephrine is started at 2-5 mcg per minute and can rise as high as 35-90 mcg per minute.[29]

If norepinephrine cannot restore the mean arterial pressure to 65 mmHg or more, then vasopressin can be added as a second-line agent.[29] This can rise to 0.03 mcg per minute. If the mean arterial pressure is still not restored then epinephrine can be added at 20-50 mcg per minute.[29]

Vasopressors are typically given through a central venous catheter.[64] If the placement of a central venous catheter is delayed then norepinephrine can be given through a peripheral IV.[64] Vasopressors are given through a central venous catheter due to concerns over tissue injury and damage that can occur if they are given through a peripheral IV.[65] In more recent years it has been shown, however, that giving vasopressors through a peripheral IV is safe for short-term use and offers practical advantages.[65]

Corticosteroids

Corticosteroids are recommended for patients with septic shock requiring vasopressors.[66] The most common regimen of corticosteroids for patients with septic shock is 200-300 mg/ day of hydrocortisone for 5-7 days.[66] This can be administered as a continuous infusion or given in divided doses.[66]

Recent evidence has shown that corticosteroids can reduce the short-term in hospital mortality associated with septic shock.[66] Corticosteroids have been shown to result in higher rates of shock reversal and reduced organ dysfunction at seven days.[66]

The adverse effects of the corticosteroids include neuromuscular weakness, however, the available evidence has shown that the benefits outweigh the risks of adverse effects for patients with septic shock.[66]

Other

β-Blockers

New evidence has shown that short-acting β-blockers can be used during the treatment of septic shock to reduce the onset of new tachyarrhythmias and have been shown to reduce 28-day mortality.[67] However, it has also been shown that β-blockers can increase the duration that patients would need to be on vasopressors.[67]

Blood purification modalities

Blood purification modalities, such as column hemoperfusion, have been suggested as treatment options for septic shock.[29] However, the current evidence behind these treatment options is weak and they are not the standard of care for patients with septic shock.[29]

Methylene blue

Methylene blue is not listed as a current treatment in the most recent guidelines for septic shock, but is an investigational and off-label therapy.[68] There are multiple meta-analyses that suggest that methylene blue could reduce mortality in cases of septic shock.[69][70] Methylene blue has also been shown to reduce time to vasopressor discontinuation, length of ICU stay, and mechanical ventilation duration.[69][70] Some studies have suggested that methylene blue can be useful in cases of refractory shock or cathecolamine-resistant shock.[71]

Epidemiology

Sepsis has a worldwide incidence of more than 49 million cases a year, with 11 million sepsis-related deaths per year.[3] Septic shock occurs in approximately 8-10% of ICU admissions.[72] Septic shock has a mortality rate of 40 percent despite advances in care.[72] About one third of hospital deaths are due to sepsis in the United States and healthcare costs associated with sepsis exceeded 38 billion in 2017.[12]

The risk of septic shock increases at age 60, with those at age 70 having the highest risk of dying from sepsis.[12]

The mortality rate from sepsis, especially if it is not treated rapidly with the needed medications in a hospital, is approximately 40% in adults and 25% in children.[73][74] The in-hospital mortality for septic shock specifically has been shown to increase 1.8% for each additional hour that antibiotics are not administered after the patient has arrived in the emergency department.[29]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Gauer, Robert; Forbes, Damon; Boyer, Nathan (2020-04-01). "Sepsis: Diagnosis and Management". American Family Physician 101 (7): 409–418. ISSN 1532-0650. PMID 32227831. 
  2. ↑ 2.0 2.1 2.2 Guarino, Matteo; Perna, Benedetta; Cesaro, Alice Eleonora; Maritati, Martina; Spampinato, Michele Domenico; Contini, Carlo; De Giorgio, Roberto (2023-04-28). "2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department" (in en). Journal of Clinical Medicine 12 (9): 3188. doi:10.3390/jcm12093188. ISSN 2077-0383. PMID 37176628. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Cecconi, Maurizio; Evans, Laura; Levy, Mitchell; Rhodes, Andrew (July 2018). "Sepsis and septic shock" (in en). The Lancet 392 (10141): 75–87. doi:10.1016/S0140-6736(18)30696-2. PMID 29937192. Bibcode: 2018Lanc..392...75C. https://linkinghub.elsevier.com/retrieve/pii/S0140673618306962. 
  4. ↑ Gupta, Shipra; Sakhuja, Ankit; Kumar, Gagan; McGrath, Eric; Nanchal, Rahul S.; Kashani, Kianoush B. (December 2016). "Culture-Negative Severe Sepsis" (in en). Chest 150 (6): 1251–1259. doi:10.1016/j.chest.2016.08.1460. PMID 27615024. https://linkinghub.elsevier.com/retrieve/pii/S0012369216589569. 
  5. ↑ Novosad, Shannon A.; Sapiano, Mathew R.P.; Grigg, Cheri; Lake, Jason; Robyn, Misha; Dumyati, Ghinwa; Felsen, Christina; Blog, Debra et al. (2016-08-26). "Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors and Opportunities for Prevention". MMWR. Morbidity and Mortality Weekly Report 65 (33): 864–869. doi:10.15585/mmwr.mm6533e1. ISSN 0149-2195. PMID 27559759. http://www.cdc.gov/mmwr/volumes/65/wr/mm6533e1.htm. 
  6. ↑ 6.0 6.1 6.2 Mayr, Florian B; Yende, Sachin; Angus, Derek C (January 2014). "Epidemiology of severe sepsis" (in en). Virulence 5 (1): 4–11. doi:10.4161/viru.27372. ISSN 2150-5594. PMID 24335434. 
  7. ↑ Ward, Peter A; Fattahi, Fatemeh (2019-06-27). "New strategies for treatment of infectious sepsis" (in en). Journal of Leukocyte Biology 106 (1): 187–192. doi:10.1002/JLB.4MIR1118-425R. ISSN 1938-3673. PMID 30821872. https://academic.oup.com/jleukbio/article/106/1/187/6935530. 
  8. ↑ 8.0 8.1 "Severe sepsis and septic shock". N. Engl. J. Med. 369 (9): 840–51. August 2013. doi:10.1056/NEJMra1208623. PMID 23984731. 
  9. ↑ "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Crit. Care Med. 41 (2): 580–637. February 2013. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. 
  10. ↑ 10.0 10.1 10.2 10.3 Cecconi, Maurizio; Evans, Laura; Levy, Mitchell; Rhodes, Andrew (July 2018). "Sepsis and septic shock" (in en). The Lancet 392 (10141): 75–87. doi:10.1016/S0140-6736(18)30696-2. PMID 29937192. Bibcode: 2018Lanc..392...75C. https://linkinghub.elsevier.com/retrieve/pii/S0140673618306962. 
  11. ↑ 11.0 11.1 11.2 Seymour, Christopher W.; Liu, Vincent X.; Iwashyna, Theodore J.; Brunkhorst, Frank M.; Rea, Thomas D.; Scherag, André; Rubenfeld, Gordon; Kahn, Jeremy M. et al. (2016-02-23). "Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)" (in en). JAMA 315 (8): 762–774. doi:10.1001/jama.2016.0288. ISSN 0098-7484. PMID 26903335. Bibcode: 2016JAMA..315..762S. 
  12. ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 Meyer, Nuala J.; Prescott, Hallie C. (2024-12-05). Hardin, C. Corey. ed. "Sepsis and Septic Shock" (in en). New England Journal of Medicine 391 (22): 2133–2146. doi:10.1056/NEJMra2403213. ISSN 0028-4793. PMID 39774315. http://www.nejm.org/doi/10.1056/NEJMra2403213. 
  13. ↑ Shields, Andrea D.; Plante, Lauren A.; Pacheco, Luis D.; Louis, Judette M. (September 2023). "Society for Maternal-Fetal Medicine Consult Series #67: Maternal sepsis" (in en). American Journal of Obstetrics and Gynecology 229 (3): B2–B19. doi:10.1016/j.ajog.2023.05.019. PMID 37236495. https://linkinghub.elsevier.com/retrieve/pii/S0002937823003277. 
  14. ↑ 14.0 14.1 14.2 14.3 14.4 van der Poll, Tom; Opal, Steven M (January 2008). "Host–pathogen interactions in sepsis" (in en). The Lancet Infectious Diseases 8 (1): 32–43. doi:10.1016/S1473-3099(07)70265-7. PMID 18063412. https://linkinghub.elsevier.com/retrieve/pii/S1473309907702657. 
  15. ↑ Lappin, Emma; Ferguson, Andrew J (May 2009). "Gram-positive toxic shock syndromes" (in en). The Lancet Infectious Diseases 9 (5): 281–290. doi:10.1016/S1473-3099(09)70066-0. PMID 19393958. https://linkinghub.elsevier.com/retrieve/pii/S1473309909700660. 
  16. ↑ 16.0 16.1 16.2 16.3 Hedayat, Mona; Netea, Mihai G; Rezaei, Nima (September 2011). "Targeting of Toll-like receptors: a decade of progress in combating infectious diseases" (in en). The Lancet Infectious Diseases 11 (9): 702–712. doi:10.1016/S1473-3099(11)70099-8. PMID 21719349. https://linkinghub.elsevier.com/retrieve/pii/S1473309911700998. 
  17. ↑ Zhang, Frank X.; Kirschning, Carsten J.; Mancinelli, Roberta; Xu, Xiao-Ping; Jin, Yiping; Faure, Emmanuelle; Mantovani, Alberto; Rothe, Mike et al. (March 1999). "Bacterial Lipopolysaccharide Activates Nuclear Factor-κB through Interleukin-1 Signaling Mediators in Cultured Human Dermal Endothelial Cells and Mononuclear Phagocytes" (in en). Journal of Biological Chemistry 274 (12): 7611–7614. doi:10.1074/jbc.274.12.7611. PMID 10075645. 
  18. ↑ Ciesielska, Anna; Matyjek, Marta; Kwiatkowska, Katarzyna (February 2021). "TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling" (in en). Cellular and Molecular Life Sciences 78 (4): 1233–1261. doi:10.1007/s00018-020-03656-y. ISSN 1420-682X. PMID 33057840. https://link.springer.com/10.1007/s00018-020-03656-y. 
  19. ↑ 19.0 19.1 Gabarin, Ramy S.; Li, Manshu; Zimmel, Paige A.; Marshall, John C.; Li, Yimin; Zhang, Haibo (2021). "Intracellular and Extracellular Lipopolysaccharide Signaling in Sepsis: Avenues for Novel Therapeutic Strategies" (in en). Journal of Innate Immunity 13 (6): 323–332. doi:10.1159/000515740. ISSN 1662-811X. PMID 34004605. 
  20. ↑ 20.0 20.1 20.2 20.3 20.4 Cheng, Lingxia; Cao, Yu; Liu, Shihao; Lv, Lukai; Zhang, Jianjun; Bao, Ji; Wang, Guan; Xu, Ping (September 2025). "Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective" (in en). International Journal of Surgery 111 (9): 6260–6289. doi:10.1097/JS9.0000000000002668. ISSN 1743-9159. https://journals.lww.com/10.1097/JS9.0000000000002668. 
  21. ↑ 21.0 21.1 "Compensatory anti-inflammatory response syndrome". Thromb. Haemost. 101 (1): 36–47. January 2009. doi:10.1160/TH08-07-0421. ISSN 0340-6245. PMID 19132187. 
  22. ↑ YashRoy, R.C. (June 1994). "Liver damage by intra-ileal treatment with Salmonella 3,10:r:- extract as studied by light and electron microscopy". Indian Journal of Animal Sciences 64 (6): 597–99. https://www.researchgate.net/publication/230820149. (animal study).
  23. ↑ "Structural Relationship of the Lipid A Acyl Groups to Activation of Murine Toll-Like Receptor 4 by Lipopolysaccharides from Pathogenic Strains of Burkholderia mallei, Acinetobacter baumannii, and Pseudomonas aeruginosa". Front Immunol 6: 595. 2015. doi:10.3389/fimmu.2015.00595. PMID 26635809. 
  24. ↑ "Septic Shock: Practice Essentials, Background, Pathophysiology". Medscape. 2024-06-26. https://emedicine.medscape.com/article/168402-overview?form=fpf. 
  25. ↑ Tusgul, Selin; Carron, Pierre-Nicolas; Yersin, Bertrand; Calandra, Thierry; Dami, Fabrice (2017-11-03). "Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage". Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 25 (1). doi:10.1186/s13049-017-0449-y. ISSN 1757-7241. PMID 29100549. 
  26. ↑ "Sepsis: Management, Including Sepsis Bundles", SpringerReference (Berlin/Heidelberg: Springer-Verlag), 2011, doi:10.1007/springerreference_301188, http://www.springerreference.com/index/doi/10.1007/springerreference_301188, retrieved 2026-01-12 
  27. ↑ Kaukonen, Kirsi-Maija; Bailey, Michael; Pilcher, David; Cooper, D. Jamie; Bellomo, Rinaldo (2015-04-23). "Systemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis" (in en). New England Journal of Medicine 372 (17): 1629–1638. doi:10.1056/NEJMoa1415236. ISSN 0028-4793. PMID 25776936. http://www.nejm.org/doi/10.1056/NEJMoa1415236. 
  28. ↑ 28.0 28.1 28.2 28.3 28.4 Singer, Mervyn; Deutschman, Clifford S.; Seymour, Christopher Warren; Shankar-Hari, Manu; Annane, Djillali; Bauer, Michael; Bellomo, Rinaldo; Bernard, Gordon R. et al. (2016-02-23). "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)" (in en). JAMA 315 (8): 801–810. doi:10.1001/jama.2016.0287. ISSN 0098-7484. PMID 26903338. 
  29. ↑ 29.00 29.01 29.02 29.03 29.04 29.05 29.06 29.07 29.08 29.09 29.10 29.11 29.12 29.13 29.14 29.15 Evans, Laura; Rhodes, Andrew; Alhazzani, Waleed; Antonelli, Massimo; Coopersmith, Craig M.; French, Craig; Machado, Flávia R.; Mcintyre, Lauralyn et al. (November 2021). "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021" (in en). Critical Care Medicine 49 (11): e1063–e1143. doi:10.1097/CCM.0000000000005337. ISSN 0090-3493. PMID 34605781. https://journals.lww.com/10.1097/CCM.0000000000005337. 
  30. ↑ Raith, Eamon P.; Udy, Andrew A.; Bailey, Michael; McGloughlin, Steven; MacIsaac, Christopher; Bellomo, Rinaldo; Pilcher, David V.; for the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE) (2017-01-17). "Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit" (in en). JAMA 317 (3): 290–300. doi:10.1001/jama.2016.20328. ISSN 0098-7484. PMID 28114553. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.20328. 
  31. ↑ Raith, Eamon P.; Udy, Andrew A.; Bailey, Michael; McGloughlin, Steven; MacIsaac, Christopher; Bellomo, Rinaldo; Pilcher, David V.; for the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE) (2017-01-17). "Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit" (in en). JAMA 317 (3): 290–300. doi:10.1001/jama.2016.20328. ISSN 0098-7484. PMID 28114553. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.20328. 
  32. ↑ 32.0 32.1 Standl, Thomas; Annecke, Thorsten; Cascorbi, Ingolf; Heller, Axel R.; Sabashnikov, Anton; Teske, Wolfram (2018-11-09). "The Nomenclature, Definition and Distinction of Types of Shock". Deutsches Ärzteblatt International 115 (45): 757–768. doi:10.3238/arztebl.2018.0757. ISSN 1866-0452. PMID 30573009. 
  33. ↑ 33.0 33.1 33.2 33.3 33.4 Yealy, Donald M.; Mohr, Nicholas M.; Shapiro, Nathan I.; Venkatesh, Arjun; Jones, Alan E.; Self, Wesley H. (July 2021). "Early Care of Adults With Suspected Sepsis in the Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report" (in en). Annals of Emergency Medicine 78 (1): 1–19. doi:10.1016/j.annemergmed.2021.02.006. PMID 33840511. https://linkinghub.elsevier.com/retrieve/pii/S0196064421001177. 
  34. ↑ 34.0 34.1 Shankar-Hari, Manu; Phillips, Gary S.; Levy, Mitchell L.; Seymour, Christopher W.; Liu, Vincent X.; Deutschman, Clifford S.; Angus, Derek C.; Rubenfeld, Gordon D. et al. (2016-02-23). "Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)" (in en). JAMA 315 (8): 775–787. doi:10.1001/jama.2016.0289. ISSN 0098-7484. PMID 26903336. 
  35. ↑ De Backer, Daniel; Ricottilli, Francesco; Ospina-Tascón, Gustavo A. (April 2021). "Septic shock: a microcirculation disease" (in en). Current Opinion in Anaesthesiology 34 (2): 85–91. doi:10.1097/ACO.0000000000000957. ISSN 0952-7907. PMID 33577205. https://journals.lww.com/10.1097/ACO.0000000000000957. 
  36. ↑ 36.0 36.1 36.2 Bakker, Jan; Postelnicu, Radu; Mukherjee, Vikramjit (January 2020). "Lactate" (in en). Critical Care Clinics 36 (1): 115–124. doi:10.1016/j.ccc.2019.08.009. PMID 31733674. https://linkinghub.elsevier.com/retrieve/pii/S0749070419300727. 
  37. ↑ 37.0 37.1 Meyer, Nuala J.; Prescott, Hallie C. (2024-12-05). Hardin, C. Corey. ed. "Sepsis and Septic Shock" (in en). New England Journal of Medicine 391 (22): 2133–2146. doi:10.1056/NEJMra2403213. ISSN 0028-4793. PMID 39774315. http://www.nejm.org/doi/10.1056/NEJMra2403213. 
  38. ↑ 38.0 38.1 Thomas-Rüddel, Daniel O.; Hoffmann, Peter; Schwarzkopf, Daniel; Scheer, Christian; Bach, Friedhelm; Komann, Marcus; Gerlach, Herwig; Weiss, Manfred et al. (December 2021). "Fever and hypothermia represent two populations of sepsis patients and are associated with outside temperature" (in en). Critical Care 25 (1). doi:10.1186/s13054-021-03776-2. ISSN 1364-8535. PMID 34674733. 
  39. ↑ Sonneville, Romain; Benghanem, Sarah; Jeantin, Lina; de Montmollin, Etienne; Doman, Marc; Gaudemer, Augustin; Thy, Michael; Timsit, Jean-François (2023-10-05). "The spectrum of sepsis-associated encephalopathy: a clinical perspective" (in en). Critical Care 27 (1). doi:10.1186/s13054-023-04655-8. ISSN 1364-8535. PMID 37798769. 
  40. ↑ Khan, Jaffar; Harrison, Taylor B.; Rich, Mark M.; Moss, Marc (2006-10-24). "Early development of critical illness myopathy and neuropathy in patients with severe sepsis" (in en). Neurology 67 (8): 1421–1425. doi:10.1212/01.wnl.0000239826.63523.8e. ISSN 0028-3878. PMID 17060568. https://www.neurology.org/doi/10.1212/01.wnl.0000239826.63523.8e. 
  41. ↑ Wagenlehner, Florian M. E.; Pilatz, Adrian; Weidner, Wolfgang; Naber, Kurt G. (2015-09-04). Mulvey, Matthew A.; Stapleton, Ann E.; Klumpp, David J.. eds. "Urosepsis: Overview of the Diagnostic and Treatment Challenges" (in en). Microbiology Spectrum 3 (5). doi:10.1128/microbiolspec.UTI-0003-2012. ISSN 2165-0497. PMID 26542042. https://journals.asm.org/doi/10.1128/microbiolspec.UTI-0003-2012. 
  42. ↑ Pulido-Perez, Ana; Sanchez-Carrillo, Carlos; Bergon-Sendin, Marta; Suarez-Fernandez, Ricardo; Rosell-Diaz, Angel Manuel; Muñoz, Patricia; Bouza, Emilio (May 2022). "Prevalence and clinical features of secondary skin lesions in septic patients with bloodstream infections" (in en). European Journal of Clinical Microbiology & Infectious Diseases 41 (5): 779–786. doi:10.1007/s10096-022-04431-6. ISSN 0934-9723. PMID 35320429. https://link.springer.com/10.1007/s10096-022-04431-6. 
  43. ↑ Yealy, Donald M.; Mohr, Nicholas M.; Shapiro, Nathan I.; Venkatesh, Arjun; Jones, Alan E.; Self, Wesley H. (July 2021). "Early Care of Adults With Suspected Sepsis in the Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report" (in en). Annals of Emergency Medicine 78 (1): 1–19. doi:10.1016/j.annemergmed.2021.02.006. PMID 33840511. https://linkinghub.elsevier.com/retrieve/pii/S0196064421001177. 
  44. ↑ Chambers, Henry F.; Bayer, Arnold S. (2020-08-06). Solomon, Caren G.. ed. "Native-Valve Infective Endocarditis" (in en). New England Journal of Medicine 383 (6): 567–576. doi:10.1056/NEJMcp2000400. ISSN 0028-4793. PMID 32757525. http://www.nejm.org/doi/10.1056/NEJMcp2000400. 
  45. ↑ Feller-Kopman, David; Light, Richard (2018-02-22). Ingelfinger, Julie R.. ed. "Pleural Disease" (in en). New England Journal of Medicine 378 (8): 740–751. doi:10.1056/NEJMra1403503. ISSN 0028-4793. PMID 29466146. http://www.nejm.org/doi/10.1056/NEJMra1403503. 
  46. ↑ Bonomo, Robert A; Chow, Anthony W; Edwards, Morven S; Humphries, Romney; Tamma, Pranita D; Abrahamian, Fredrick M; Bessesen, Mary; Dellinger, E Patchen et al. (2024-10-04). "2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Complicated Intra-abdominal Infections: Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation in Adults, Children, and Pregnant People" (in en). Clinical Infectious Diseases 79 (Supplement_3): S81–S87. doi:10.1093/cid/ciae346. ISSN 1058-4838. PMID 38965057. https://academic.oup.com/cid/article/79/Supplement_3/S81/7706348. 
  47. ↑ Achanti, Anand; Szerlip, Harold M. (January 2023). "Acid-Base Disorders in the Critically Ill Patient" (in en). Clinical Journal of the American Society of Nephrology 18 (1): 102–112. doi:10.2215/CJN.04500422. ISSN 1555-9041. PMID 35998977. 
  48. ↑ O'Grady, Naomi; Alexander, Earnest; Alhazzani, Waleed; Alshamsi, Fayez; Cuellar-Rodriguez, Jennifer; Jefferson, Brian K.; Kalil, Andre C.; Pastores, Stephen M. et al. (November 2023). "Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU" (in en). Critical Care Medicine 51 (11): 1570–1586. doi:10.1097/CCM.0000000000006022. ISSN 0090-3493. PMID 37902340. https://journals.lww.com/10.1097/CCM.0000000000006022. 
  49. ↑ 49.0 49.1 Kaal, Anna G.; Nieberg, Margot; Stegmeijer, Koen; Steyerberg, Ewout W.; van Nieuwkoop, Cees (January 2026). "The diagnostic accuracy of procalcitonin for community-acquired bacteremia: an updated systematic review and meta-analysis" (in en). Clinical Microbiology and Infection. doi:10.1016/j.cmi.2025.12.029. PMID 41519266. https://linkinghub.elsevier.com/retrieve/pii/S1198743X2500655X. 
  50. ↑ on behalf of the Internal Medicine Sepsis Study Group; Tosoni, Alberto; Paratore, Mattia; Piscitelli, Pamela; Addolorato, Giovanni; De Cosmo, Salvatore; Mirijello, Antonio (March 2020). "The use of procalcitonin for the management of sepsis in Internal Medicine wards: current evidence". Panminerva Medica 62 (1): 54–62. doi:10.23736/S0031-0808.19.03809-6. PMID 31729202. https://www.minervamedica.it/index2.php?show=R41Y2020N01A0054. 
  51. ↑ 51.0 51.1 51.2 Levinson, A.T.; Casserly, B.P.; Levy, M.M. (April 2011). "Reducing mortality in severe sepsis and septic shock". Seminars in Respiratory and Critical Care Medicine 32 (2): 195–205. doi:10.1055/s-0031-1275532. PMID 21506056. 
  52. ↑ Zampieri, Fernando G.; Bagshaw, Sean M.; Semler, Matthew W. (2023-06-13). "Fluid Therapy for Critically Ill Adults With Sepsis: A Review" (in en). JAMA 329 (22): 1967–1980. doi:10.1001/jama.2023.7560. ISSN 0098-7484. PMID 37314271. https://jamanetwork.com/journals/jama/fullarticle/2805900. 
  53. ↑ 53.0 53.1 53.2 Meyhoff, Tine S.; Hjortrup, Peter B.; Wetterslev, Jørn; Sivapalan, Praleene; Laake, Jon H.; Cronhjort, Maria; Jakob, Stephan M.; Cecconi, Maurizio et al. (2022-06-30). "Restriction of Intravenous Fluid in ICU Patients with Septic Shock" (in en). New England Journal of Medicine 386 (26): 2459–2470. doi:10.1056/NEJMoa2202707. ISSN 0028-4793. PMID 35709019. http://www.nejm.org/doi/10.1056/NEJMoa2202707. 
  54. ↑ Paul, M.; Dickstein, Y.; Raz-Pasteur, A. (December 2016). "Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis" (in en). Clinical Microbiology and Infection 22 (12): 960–967. doi:10.1016/j.cmi.2016.05.023. PMID 27283148. http://linkinghub.elsevier.com/retrieve/pii/S1198743X16301756. 
  55. ↑ O'Grady, Naomi P.; Alexander, Earnest; Alhazzani, Waleed; Alshamsi, Fayez; Cuellar-Rodriguez, Jennifer; Jefferson, Brian K.; Kalil, Andre C.; Pastores, Stephen M. et al. (November 2023). "Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU" (in en). Critical Care Medicine 51 (11): 1570–1586. doi:10.1097/CCM.0000000000006022. ISSN 0090-3493. PMID 37902340. https://journals.lww.com/10.1097/CCM.0000000000006022. 
  56. ↑ 56.0 56.1 56.2 Hasbun, Rodrigo (2022-12-06). "Progress and Challenges in Bacterial Meningitis: A Review" (in en). JAMA 328 (21): 2147–2154. doi:10.1001/jama.2022.20521. ISSN 0098-7484. PMID 36472590. https://jamanetwork.com/journals/jama/fullarticle/2799148. 
  57. ↑ 57.0 57.1 Vaughn, Valerie M.; Dickson, Robert P.; Horowitz, Jennifer K.; Flanders, Scott A. (2024-10-15). "Community-Acquired Pneumonia: A Review" (in en). JAMA 332 (15): 1282–1295. doi:10.1001/jama.2024.14796. ISSN 0098-7484. PMID 39283629. https://jamanetwork.com/journals/jama/fullarticle/2823762. 
  58. ↑ 58.0 58.1 Hasbun, Rodrigo (2022-12-06). "Progress and Challenges in Bacterial Meningitis: A Review" (in en). JAMA 328 (21): 2147–2154. doi:10.1001/jama.2022.20521. ISSN 0098-7484. PMID 36472590. https://jamanetwork.com/journals/jama/fullarticle/2799148. 
  59. ↑ "Stevens DL et al (Clin Infect Dis 2014; 59:147–59)" (in en). Clinical Infectious Diseases 60 (9): 1448. 2015-05-01. doi:10.1093/cid/civ114. ISSN 1537-6591. PMID 25725056. https://academic.oup.com/cid/article/60/9/1448/406029. 
  60. ↑ Hua, Camille; Urbina, Tomas; Bosc, Romain; Parks, Tom; Sriskandan, Shiranee; de Prost, Nicolas; Chosidow, Olivier (March 2023). "Necrotising soft-tissue infections" (in en). The Lancet Infectious Diseases 23 (3): e81–e94. doi:10.1016/S1473-3099(22)00583-7. PMID 36252579. https://linkinghub.elsevier.com/retrieve/pii/S1473309922005837. 
  61. ↑ 61.0 61.1 Mazuski, John E.; Tessier, Jeffrey M.; May, Addison K.; Sawyer, Robert G.; Nadler, Evan P.; Rosengart, Matthew R.; Chang, Phillip K.; O'Neill, Patrick J. et al. (January 2017). "The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection". Surgical Infections 18 (1): 1–76. doi:10.1089/sur.2016.261. ISSN 1096-2964. PMID 28085573. https://www.liebertpub.com/doi/10.1089/sur.2016.261. 
  62. ↑ 62.0 62.1 Taplitz, Randy A.; Kennedy, Erin B.; Bow, Eric J.; Crews, Jennie; Gleason, Charise; Hawley, Douglas K.; Langston, Amelia A.; Nastoupil, Loretta J. et al. (2018-05-10). "Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update" (in en). Journal of Clinical Oncology 36 (14): 1443–1453. doi:10.1200/JCO.2017.77.6211. ISSN 0732-183X. PMID 29461916. https://ascopubs.org/doi/10.1200/JCO.2017.77.6211. 
  63. ↑ 63.0 63.1 Colon Hidalgo, Daniel; Patel, Jaimini; Masic, Dalila; Park, David; Rech, Megan A. (February 2020). "Delayed vasopressor initiation is associated with increased mortality in patients with septic shock" (in en). Journal of Critical Care 55: 145–148. doi:10.1016/j.jcrc.2019.11.004. PMID 31731173. https://linkinghub.elsevier.com/retrieve/pii/S0883944119309116. 
  64. ↑ 64.0 64.1 Munroe, Elizabeth S.; Co, Ivan N.; Douglas, Ivor; Hyzy, Robert; Khan, Akram; Nelson, Kristine; Park, Pauline K.; Peltan, Ithan D. et al. (2025-08-27). "Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension" (in en). JAMA Network Open 8 (8): e2529148. doi:10.1001/jamanetworkopen.2025.29148. ISSN 2574-3805. PMID 40864467. 
  65. ↑ 65.0 65.1 Tran, Quincy K.; Mester, Gaurika; Bzhilyanskaya, Vera; Afridi, Leenah Z.; Andhavarapu, Sanketh; Alam, Zain; Widjaja, Austin; Andersen, Brooke et al. (November 2020). "Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis" (in en). The American Journal of Emergency Medicine 38 (11): 2434–2443. doi:10.1016/j.ajem.2020.09.047. PMID 33039229. https://linkinghub.elsevier.com/retrieve/pii/S0735675720308421. 
  66. ↑ 66.0 66.1 66.2 66.3 66.4 66.5 Chaudhuri, Dipayan; Nei, Andrea M.; Rochwerg, Bram; Balk, Robert A.; Asehnoune, Karim; Cadena, Rhonda; Carcillo, Joseph A.; Correa, Ricardo et al. (May 2024). "2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia" (in en). Critical Care Medicine 52 (5): e219–e233. doi:10.1097/CCM.0000000000006172. ISSN 0090-3493. PMID 38240492. https://journals.lww.com/10.1097/CCM.0000000000006172. 
  67. ↑ 67.0 67.1 McChesney, Chris; Orozco, Nicolas; Fiorini, Kyle; Wong, Michelle Yee Suet; Slessarev, Marat; Prager, Ross; Kao, Raymond; Leligdowicz, Aleksandra et al. (May 2025). "Impact of Short-Acting Beta-Blockers on the Outcomes of Patients With Septic Shock: A Systematic Review and Meta-Analysis" (in en). Critical Care Medicine 53 (5): e1125–e1139. doi:10.1097/CCM.0000000000006604. ISSN 0090-3493. PMID 40009025. https://journals.lww.com/10.1097/CCM.0000000000006604. 
  68. ↑ Jia, Jinxin; Ji, Jingjing; Liu, Zhifeng (2024-09-27). "Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial" (in en). Trials 25 (1). doi:10.1186/s13063-024-08439-5. ISSN 1745-6215. PMID 39334256. 
  69. ↑ 69.0 69.1 Ballarin, Raquel Simões; Lazzarin, Taline; Zornoff, Leonardo; Azevedo, Paula Schmidt; Pereira, Filipe Welson Leal; Tanni, Suzana Erico; Minicucci, Marcos Ferreira (2024-04-18). "Methylene blue in sepsis and septic shock: a systematic review and meta-analysis". Frontiers in Medicine 11. doi:10.3389/fmed.2024.1366062. ISSN 2296-858X. PMID 38698779. 
  70. ↑ 70.0 70.1 Alkazemi, Afrah; Almoosawy, Sayed Abdulmotaleb; Murad, Anwar; Alfares, Abdulrahman (February 2026). "Methylene Blue for Septic Shock: A Systematic Review and Meta-analysis of Randomized and Prospective Observational Studies" (in en). Journal of Intensive Care Medicine 41 (2): 108–117. doi:10.1177/08850666241300312. ISSN 0885-0666. PMID 39574288. https://journals.sagepub.com/doi/10.1177/08850666241300312. 
  71. ↑ Pluta, Michał P.; Putowski, Zbigniew; Czempik, Piotr F.; Krzych, Łukasz J. (2023-06-28). "Successful Use of Methylene Blue in Catecholamine-Resistant Septic Shock: A Case Report and Short Literature Review" (in en). International Journal of Molecular Sciences 24 (13): 10772. doi:10.3390/ijms241310772. ISSN 1422-0067. PMID 37445952. 
  72. ↑ 72.0 72.1 Vincent, Jean-Louis; Jones, Gabriel; David, Sholto; Olariu, Elena; Cadwell, Kevin K. (December 2019). "Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis" (in en). Critical Care 23 (1). doi:10.1186/s13054-019-2478-6. ISSN 1364-8535. PMID 31151462. 
  73. ↑ Bauer, Michael; Gerlach, Herwig; Vogelmann, Tobias; Preissing, Franziska; Stiefel, Julia; Adam, Daniel (December 2020). "Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019— results from a systematic review and meta-analysis" (in en). Critical Care 24 (1). doi:10.1186/s13054-020-02950-2. ISSN 1364-8535. PMID 32430052. 
  74. ↑ Tan, Bobby; Wong, Judith Ju-Ming; Sultana, Rehena; Koh, Janine Cynthia Jia Wen; Jit, Mark; Mok, Yee Hui; Lee, Jan Hau (2019-04-01). "Global Case-Fatality Rates in Pediatric Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis" (in en). JAMA Pediatrics 173 (4): 352–362. doi:10.1001/jamapediatrics.2018.4839. ISSN 2168-6203. PMID 30742207. 
Classification
External resources



Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Septic_shock&oldid=4239190"